{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-089845","form_type":"8-K","ticker":"ONCO","cik":"0001782107","company_name":"Onconetix, Inc.","filed_at":"2025-09-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.971763+00:00","generated_at":"2026-05-17T05:59:22.602630+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Onconetix subsidiary Proteomedix licenses manufacturing IP for PancreaSure test to Immunovia","bullets":["Proteomedix provides master cell lines and IP for three of five PancreaSure biomarkers.","Immunovia pays $700K total: two $300K payments (Sep 2025, Mar 2026) plus $100K for materials.","Immunovia to pay 3% royalty on net sales of PancreaSure from 2026 through 2032.","Deal enables Immunovia to purchase reagents directly from Proteomedix's supplier.","Onconetix remains focused on commercializing its own Proclarix prostate cancer test."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-089845","json":"https://secwatch.observer/filing/0001213900-25-089845.json","markdown":"https://secwatch.observer/filing/0001213900-25-089845.md","text":"https://secwatch.observer/filing/0001213900-25-089845.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025089845/0001213900-25-089845-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025089845/ea0258196-8k_onconetix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:59:22.602630+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}